WO1999006540A3 - Inhibitors of cell-cycle progression and uses related thereto - Google Patents

Inhibitors of cell-cycle progression and uses related thereto Download PDF

Info

Publication number
WO1999006540A3
WO1999006540A3 PCT/US1998/015759 US9815759W WO9906540A3 WO 1999006540 A3 WO1999006540 A3 WO 1999006540A3 US 9815759 W US9815759 W US 9815759W WO 9906540 A3 WO9906540 A3 WO 9906540A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
cell
cycle progression
uses related
cyclin
Prior art date
Application number
PCT/US1998/015759
Other languages
French (fr)
Other versions
WO1999006540A2 (en
Inventor
Jeno Gyuris
Lou Lamphere
David H Beach
Original Assignee
Mitotix Inc
Jeno Gyuris
Lou Lamphere
David H Beach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitotix Inc, Jeno Gyuris, Lou Lamphere, David H Beach filed Critical Mitotix Inc
Priority to AU86014/98A priority Critical patent/AU752152B2/en
Priority to EP98937264A priority patent/EP1000166A2/en
Priority to CA002298115A priority patent/CA2298115A1/en
Priority to JP2000505282A priority patent/JP2001512008A/en
Publication of WO1999006540A2 publication Critical patent/WO1999006540A2/en
Publication of WO1999006540A3 publication Critical patent/WO1999006540A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Abstract

The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.
PCT/US1998/015759 1997-07-29 1998-07-29 Inhibitors of cell-cycle progression and uses related thereto WO1999006540A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU86014/98A AU752152B2 (en) 1997-07-29 1998-07-29 Inhibitors of cell-cycle progression and uses related thereto
EP98937264A EP1000166A2 (en) 1997-07-29 1998-07-29 Inhibitors of cell-cycle progression and uses related thereto
CA002298115A CA2298115A1 (en) 1997-07-29 1998-07-29 Inhibitors of cell-cycle progression and uses related thereto
JP2000505282A JP2001512008A (en) 1997-07-29 1998-07-29 Cell cycle progression inhibitors and related uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/902,572 1997-07-29
US08/902,572 US6495526B2 (en) 1996-01-23 1997-07-29 Inhibitors of cell-cycle progression and uses related thereto

Publications (2)

Publication Number Publication Date
WO1999006540A2 WO1999006540A2 (en) 1999-02-11
WO1999006540A3 true WO1999006540A3 (en) 1999-12-16

Family

ID=25416041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015759 WO1999006540A2 (en) 1997-07-29 1998-07-29 Inhibitors of cell-cycle progression and uses related thereto

Country Status (6)

Country Link
US (1) US6495526B2 (en)
EP (1) EP1000166A2 (en)
JP (1) JP2001512008A (en)
AU (1) AU752152B2 (en)
CA (1) CA2298115A1 (en)
WO (1) WO1999006540A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420345B1 (en) 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
JP2003523722A (en) * 1999-03-01 2003-08-12 セル ジェネシス インコーポレイテッド Antineoplastic compositions and uses thereof
US6413943B1 (en) 1999-03-01 2002-07-02 Cell Genesys, Inc. Methods and reagents for inhibiting proliferation of smooth muscle cells
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
CA2369884C (en) * 1999-04-12 2010-01-05 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
AU7320200A (en) 1999-09-22 2001-04-24 Hitoshi Kohsaka P21cip1 remedies for rheumatism
DE19954444A1 (en) * 1999-11-11 2001-05-31 Theragen Molekularmedizinische Method of protecting mammalian cells using overexpressed G-2 / M cell cycle couplers
AU3368301A (en) * 2000-01-07 2001-07-16 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
YU54202A (en) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
JP3854995B2 (en) * 2000-01-21 2006-12-06 関西ティー・エル・オー株式会社 Cell-permeable carrier peptide
HN2001000008A (en) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
JP2004501083A (en) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド Pyrazole for inhibiting protein kinases
MXPA03001189A (en) 2000-08-09 2004-05-14 Agouron Pharma Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases.
CA2436805A1 (en) 2000-11-07 2002-10-17 Pioneer Hi-Bred International, Inc. Cell cycle nucleic acids, polypeptides and uses thereof
KR100465589B1 (en) * 2001-04-20 2005-01-13 허만욱 Anti-obesity polypeptides
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2003072705A2 (en) * 2002-02-20 2003-09-04 Sirna Therapeutics, Inc. Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN1327899C (en) * 2003-05-10 2007-07-25 彭朝晖 Gene recombined medicine of adenovirus carrier and p53 gene for treating proliferative diseases
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
GB0507598D0 (en) * 2005-04-14 2005-05-18 Trojantec Technologies Ltd Composition
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2019014652A1 (en) * 2017-07-13 2019-01-17 Memphis Meats, Inc. Compositions and methods for increasing the efficiency of cell cultures used for food production
WO2019209538A1 (en) * 2018-04-27 2019-10-31 The Regents Of The University Of California Compositions and methods involving engineered p27

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028483A1 (en) * 1994-04-14 1995-10-26 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
WO1996031534A1 (en) * 1995-04-03 1996-10-10 Sloan-Kettering Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULES ENCODING p57KIP2 AND USES OF SAME
WO1997011174A1 (en) * 1995-09-21 1997-03-27 Cyclacel Limited Cyclin depenpent kinase binding compounds
WO1997027297A1 (en) * 1996-01-23 1997-07-31 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5136022A (en) 1988-02-18 1992-08-04 Schering Corporation T cell activation markers
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5350835A (en) * 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
US5596079A (en) * 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
WO1993020834A1 (en) * 1992-04-10 1993-10-28 Brigham And Women's Hospital Methods and compositions for oral delivery of therapeutic agents
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028483A1 (en) * 1994-04-14 1995-10-26 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
WO1996031534A1 (en) * 1995-04-03 1996-10-10 Sloan-Kettering Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULES ENCODING p57KIP2 AND USES OF SAME
WO1997011174A1 (en) * 1995-09-21 1997-03-27 Cyclacel Limited Cyclin depenpent kinase binding compounds
WO1997027297A1 (en) * 1996-01-23 1997-07-31 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BJORNSSON T D ET AL.: "Acidic fibroblast growth factor promotes vascular repair", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 88, October 1991 (1991-10-01), pages 8651 - 8655, XP002090366 *
BONFANTI M ET AL: "p21 WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth", CANCER RESEARCH, vol. 57, 15 April 1997 (1997-04-15), pages 1442 - 1446, XP002087115 *
EZHEVSKY S A ET AL.: "Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D: Cdk4/6 complexes results in active pRb", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 94, September 1997 (1997-09-01), pages 10699 - 10704, XP002117662 *
FRANKEL A D AND PABO C O: "Cellular uptake of the Tat protein from human immunodeficiency virus", CELL, vol. 55, 23 December 1988 (1988-12-23), pages 1189 - 1193, XP002117661 *
LUO Y ET AL: "CELL-CYCLE INHIBITION BY INDEPENDENT CDK AND PCNA BINDING DOMAINS IN P21 CIP1", NATURE, vol. 375, no. 6527, 11 May 1995 (1995-05-11), pages 159 - 161, XP002031641 *
MACLACHLAN T K ET AL: "CYCLINS, CYCLIN-DEPENDENT KINASES AND CDK INHIBITORS: IMPLICATIONS IN CELL CYCLE CONTROL AND CANCER", CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, vol. 5, no. 2, 1 January 1995 (1995-01-01), pages 127 - 156, XP000572011 *

Also Published As

Publication number Publication date
JP2001512008A (en) 2001-08-21
AU752152B2 (en) 2002-09-05
AU8601498A (en) 1999-02-22
US20020068706A1 (en) 2002-06-06
US6495526B2 (en) 2002-12-17
WO1999006540A2 (en) 1999-02-11
EP1000166A2 (en) 2000-05-17
CA2298115A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
WO1999006540A3 (en) Inhibitors of cell-cycle progression and uses related thereto
CA2291222A1 (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
AU4920397A (en) Purine inhibitors of glycogen synthase kinase 3 (gsk3)
WO1998034121A3 (en) Isolated p27 protein and methods for its production and use
AU1926001A (en) Novel human protein kinases and protein kinase-like enzymes
WO1995033819A3 (en) Cdk4 (cyclin dependent kinase 4) binding proteins
WO2004026229A3 (en) Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
WO2000042042A3 (en) High affinity inhibitors for target validation and uses thereof
GEP20074227B (en) PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS
PL350001A1 (en) Purine inhibitors of cyclin dependent kinase 2 and iκ-aα
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
ATE309223T1 (en) CYCLIN-DEPENDENT KINASE INHIBITORS
CA2400554A1 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
AU3801997A (en) Assays for protein kinases using fluorescent protein substrates
MY137888A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MX9702307A (en) PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE.
AU2001249149A1 (en) Spray drying methods of making agglomerate abrasive grains and abrasive articles
AU4973896A (en) Ink4c-p18 and ink4d-p19, inhibitors of cyclin-depedent kinases cdk4 and cdk6, and uses thereof
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
WO1996034113A3 (en) Methods for the identification of farnesyltransferase inhibitors
WO2003033499A3 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
TR199802649A2 (en) Binding partners for inhibitors of cyclin-dependent kinases.
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
MXPA04004372A (en) Heterocyclic derivatives of glycinamide and their medical use.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2298115

Country of ref document: CA

Ref country code: CA

Ref document number: 2298115

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998937264

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 86014/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998937264

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 86014/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998937264

Country of ref document: EP